What is HC Wainwright’s Estimate for CADL Q2 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL) – Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Candel Therapeutics in a research note issued to investors on Monday, June 30th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.47) per share. HC Wainwright also issued estimates for Candel Therapeutics’ FY2025 earnings at ($0.38) EPS and FY2026 earnings at ($0.44) EPS.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.37.

Separately, Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.00.

Candel Therapeutics Stock Up 2.9%

Shares of NASDAQ:CADL opened at $4.99 on Wednesday. The company has a market capitalization of $250.00 million, a PE ratio of -3.72 and a beta of -0.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.64 and a quick ratio of 4.64. The business has a fifty day moving average price of $5.22 and a two-hundred day moving average price of $6.73. Candel Therapeutics has a 1 year low of $3.79 and a 1 year high of $14.60.

Institutional Trading of Candel Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CADL. BNP Paribas Financial Markets purchased a new stake in shares of Candel Therapeutics in the 4th quarter valued at about $30,000. Russell Investments Group Ltd. raised its holdings in shares of Candel Therapeutics by 75.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company’s stock valued at $33,000 after buying an additional 1,610 shares in the last quarter. Taylor Financial Group Inc. purchased a new position in shares of Candel Therapeutics during the 1st quarter valued at about $56,000. Private Advisor Group LLC purchased a new position in shares of Candel Therapeutics during the 1st quarter valued at about $58,000. Finally, Invesco Ltd. purchased a new position in Candel Therapeutics in the 1st quarter worth approximately $59,000. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.